New Media Department               Yu Jie, Duan Yuqing               May 26, 2023

Today, AbbVie (AbbVie) announced that the New England Journal of Medicine published a Phase 3 clinical trial results of U-EXCEL, U-EXCEED and U-ENDURE of its JAK inhibitor upadacitinib (Rinvoq) in adult patients with moderate to severe Crohn's disease (Crohn's disease). These patients are underresponsive, unresponsive, or intolerant to traditional therapies or biologics. Upatinib was just approved by the FDA this month as a once-daily oral drug for patients with moderately to severely active Crohn's disease.

Crohn's disease is a chronic systemic disease characterized by inflammation in the gastrointestinal tract or digestive tract, which can cause persistent diarrhea, abdominal pain, and rectal bleeding in episodes. It is a progressive disease that gets worse over time. Because of the unpredictable symptoms of Crohn's disease, it brings multiple physical, emotional, and financial burdens to patients.

Discovered and developed by AbbVie scientists, Upatinib is a selective and reversible JAK inhibitor that has been studied for many serious immune-mediated inflammatory diseases. Compared with JAK2, JAK3 and TYK2, upatinib showed a stronger inhibitory effect on JAK1 in cell and enzyme activity experiments. The drug is currently approved for the treatment of adult patients with moderate to severe rheumatoid arthritis, psoriatic arthritis, moderate to severe ulcerative colitis and ankylosing spondylitis. Upadatinib has been approved for the treatment of Crohn's disease in many countries and regions, including the United Kingdom, the European Union and the United States.